Literature DB >> 28608424

Evaluation of the 8th edition American Joint Commission on Cancer (AJCC) staging system for patients with intrahepatic cholangiocarcinoma: A surveillance, epidemiology, and end results (SEER) analysis.

Yuhree Kim1, Dimitrios P Moris1, Xu-Feng Zhang1, Fabio Bagante1, Gaya Spolverato1, Carl Schmidt1, Mary Dilhoff1, Timothy M Pawlik1.   

Abstract

BACKGROUND: The objective of this study was to assess the prognostic performance of American Joint Committee on Cancer (AJCC) 8th edition in patients with intrahepatic cholangiocarcinoma (ICC) using a cancer registry.
METHODS: The Surveillance, Epidemiology, and End Results (SEER) cancer registry was queried to identify 1008 patients who underwent surgical resection of ICC during 1998-2013. Kaplan-Meier method and Cox proportional hazards regression models were used to analyze long-term survival. The relative discriminative abilities were assessed using the Harrell's concordance index.
RESULTS: Median patient age was 62 years and 47.6% of the patients were male. Most tumors were T1 or T2 (n = 413, 41.0% and n = 329, 32.6%, respectively) and 22.1% of patients had lymph node (LN) metastasis. Median tumor size was 5.5 cm. With a median follow-up of 18 months, median survival was 27 months and 5-year OS was 30.6%. The OS c-index for the AJCC 8th staging system was 0.669, which was comparable with the c-index for the 7th edition AJCC staging system (c-index: 0.667); the AJCC 8th-edition did provide more discrete stratification of patients.
CONCLUSIONS: The new AJCC 8th-edition staging system for ICC was largely comparable to the 7th-edition version and did not provide a marked improvement in overall prognostic discrimination.
© 2017 Wiley Periodicals, Inc.

Entities:  

Keywords:  AJCC 8th-edition; ICC; prognostication

Mesh:

Year:  2017        PMID: 28608424     DOI: 10.1002/jso.24720

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  30 in total

1.  Comprehensive Molecular Profiling of Intrahepatic and Extrahepatic Cholangiocarcinomas: Potential Targets for Intervention.

Authors:  Maeve A Lowery; Ryan Ptashkin; Emmet Jordan; Michael F Berger; Ahmet Zehir; Marinela Capanu; Nancy E Kemeny; Eileen M O'Reilly; Imane El-Dika; William R Jarnagin; James J Harding; Michael I D'Angelica; Andrea Cercek; Jaclyn F Hechtman; David B Solit; Nikolaus Schultz; David M Hyman; David S Klimstra; Leonard B Saltz; Ghassan K Abou-Alfa
Journal:  Clin Cancer Res       Date:  2018-05-30       Impact factor: 12.531

Review 2.  Eighth Edition of the UICC Classification of Malignant Tumours: an overview of the changes in the pathological TNM classification criteria-What has changed and why?

Authors:  Luca Bertero; Federica Massa; Jasna Metovic; Roberto Zanetti; Isabella Castellano; Umberto Ricardi; Mauro Papotti; Paola Cassoni
Journal:  Virchows Arch       Date:  2017-12-05       Impact factor: 4.064

3.  Tumor-Infiltrating Lymphocytes and Macrophages in Intrahepatic Cholangiocellular Carcinoma. Impact on Prognosis after Complete Surgery.

Authors:  Luca Vigano; Cristiana Soldani; Barbara Franceschini; Matteo Cimino; Ana Lleo; Matteo Donadon; Massimo Roncalli; Alessio Aghemo; Luca Di Tommaso; Guido Torzilli
Journal:  J Gastrointest Surg       Date:  2019-01-31       Impact factor: 3.452

4.  Surgical Management of Intrahepatic Cholangiocarcinoma in Patients with Cirrhosis: Impact of Lymphadenectomy on Peri-Operative Outcomes.

Authors:  Fabio Bagante; Gaya Spolverato; Matthew Weiss; Sorin Alexandrescu; Hugo P Marques; Luca Aldrighetti; Shishir K Maithel; Carlo Pulitano; Todd W Bauer; Feng Shen; George A Poultsides; Olivier Soubrane; Guillaume Martel; B Groot Koerkamp; Alfredo Guglielmi; Endo Itaru; Andrea Ruzzenente; Timothy M Pawlik
Journal:  World J Surg       Date:  2018-08       Impact factor: 3.352

5.  Trends in the Incidence, Treatment and Outcomes of Patients with Intrahepatic Cholangiocarcinoma in the USA: Facility Type is Associated with Margin Status, Use of Lymphadenectomy and Overall Survival.

Authors:  Lu Wu; Diamantis I Tsilimigras; Anghela Z Paredes; Rittal Mehta; J Madison Hyer; Katiuscha Merath; Kota Sahara; Fabio Bagante; Eliza W Beal; Feng Shen; Timothy M Pawlik
Journal:  World J Surg       Date:  2019-07       Impact factor: 3.352

6.  Prognostic Nomogram Based on Histological Characteristics of Fibrotic Tumor Stroma in Patients Who Underwent Curative Resection for Intrahepatic Cholangiocarcinoma.

Authors:  Chu-Yu Jing; Yi-Peng Fu; Jin-Long Huang; Mei-Xia Zhang; Yong Yi; Wei Gan; Xin Xu; Hu-Jia Shen; Jia-Jia Lin; Su-Su Zheng; Juan Zhang; Jian Zhou; Jia Fan; Zheng-Gang Ren; Shuang-Jian Qiu; Bo-Heng Zhang
Journal:  Oncologist       Date:  2018-09-26

7.  Reappraisal of the T Category for Solitary Intrahepatic Cholangiocarcinoma by Tumor Size in 611 Early-Stage (T1-2N0M0) Patients After Hepatectomy: a Surveillance, Epidemiology, and End Results (SEER) Analysis.

Authors:  YiPing Chen; ShanGeng Weng
Journal:  J Gastrointest Surg       Date:  2020-11-02       Impact factor: 3.452

8.  Redefining the T1 category of the 8th American Joint Committee on Cancer Staging System for intrahepatic cholangiocarcinoma: A SEER database analysis.

Authors:  Yang Li; Chuangang Tang; Bingqing Zhao; Fang Dong
Journal:  Oncol Lett       Date:  2019-11-14       Impact factor: 2.967

9.  Pyrophosphatase 1 expression is associated with future recurrence and overall survival in Chinese patients with intrahepatic cholangiocarcinoma.

Authors:  Dongyun Xu; Yuqing Miao; Xiaoqiang Gu; Jiejun Wang; Guanzhen Yu
Journal:  Oncol Lett       Date:  2018-03-15       Impact factor: 2.967

10.  Current survival and treatment trends for surgically resected intrahepatic cholangiocarcinoma in the United States.

Authors:  Ariella M Altman; Scott Kizy; Schelomo Marmor; Jing Li Huang; Jason W Denbo; Eric H Jensen
Journal:  J Gastrointest Oncol       Date:  2018-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.